SASOL-CHEMICALS
31.3.2022 08:02:08 CEST | Business Wire | Press release
Sasol Chemicals, a business unit of Sasol Ltd. (JSE: SOL; NYSE: SSL) and Holiferm Limited announced today a partnership to jointly develop new biosurfactants and enable the broad commercialisation of sophorolipids.
Sasol Chemicals has agreed to purchase the majority of sophorolipids produced at a new Holiferm manufacturing facility in the United Kingdom, which is under construction and scheduled to begin operations in early 2023. Sasol Chemicals will also fund Holiferm research and development to accelerate innovation initiatives to help meet growing demand for sustainable solutions in primary surfactants.
Biosurfactants use natural materials to produce surfactants, which are key ingredients in detergents, cleaning products and personal care products. Sophorolipids are biosurfactants made through fermentation, using yeast to convert vegetable oils and glucose into final product. The Holiferm process offers an extensive reduction in carbon footprint comparative to conventional surfactants.
“We are increasingly using bio-based raw materials to make our products, as we work with our customers to develop solutions that in turn make their products more sustainable,” said Silke Hoppe, Vice President of Essential Care Chemicals for Sasol Chemicals. “The Holiferm expertise in the area of fermentation technology and production is a perfect fit with Sasol’s position as a global leader in the supply of surfactants and surfactant intermediates into the Fabric and Home Care, Personal Care as well as Industrial and Institutional Cleaning markets.”
Essential Care Chemicals is a global customer-focused business division dedicated to innovating sustainable solutions for people and the planet. Using in-depth knowledge of different markets, applications and products, it creates advanced high-performance solutions in the following core markets: Fabric Home Care, Industrial and Institutional Cleaning, Personal Care, Health and Wellness, and Technical Markets including Energy.
“We at Holiferm truly believe in the future of biosurfactants and fermentation technologies to reduce the dependence on fossil-based chemicals,” said Richard Lock, Managing Director of Holiferm. “The drive, passion and commitment Sasol Chemicals is showing with Holiferm Limited are a perfect fit, for both companies and the planet as a whole.”
Financial terms of the agreements between Sasol Chemicals and Holiferm Limited were not disclosed.
About Sasol Chemicals
Sasol Chemicals is a solutions provider focused on sustainability, circularity and specialties. It fulfills its purpose of “Innovating for a better world” by offering a broad, state-of-the-art portfolio of specialty and commodity chemicals for a wide range of applications and industries.
Our solutions are used by more than 7,500 customers, in 120 countries, in countless products that improve the quality of life for people around the world. They also provide the building blocks for a sustainable future by helping reduce energy usage, waste and packaging, and by providing solutions to the renewable energy industry.
Sasol Chemicals is a business of Sasol Limited, a leading chemicals and energy company focused on creating sustainable value for our stakeholders. For more information, visit the Sasol Chemicals website .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220330005575/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom